Breast Cancer: Current Research
Open Access

Tumor microenvironment; Breast cancer; Stromal cells; Immune cells; Angiogenesis; Immunotherapy; Anti-angiogenic therapy; Cancer-associated fibroblasts (CAFs); Tumor-infiltrating lymphocytes (TILs); Myeloid-derived suppressor cells (MDSCs); Tumor-associated macrophages (TAMs); Extracellular matrix (ECM); Biomarkers

Introduction

The tumor microenvironment (TME) is a dynamic and heterogeneous milieu that encompasses a variety of cellular and non-cellular components interacting with tumor cells to regulate various aspects of cancer progression. In breast cancer, the TME plays a pivotal role in shaping tumor behavior, influencing treatment response, and ultimately determining patient outcomes. Understanding the complex interplay between tumor cells and the surrounding microenvironment is essential for developing effective therapeutic strategies that target the TME and improve treatment outcomes in breast cancer patients [1].

Methodology

Components of the tumor microenvironment: The TME in breast cancer is characterized by a diverse array of cell types, including cancer-associated fibroblasts (CAFs), immune cells, endothelial cells, and adipocytes, as well as extracellular matrix (ECM) components such as collagen, fibronectin, and hyaluronic acid. These components interact with each other and with tumor cells through various signaling pathways, cytokines, and growth factors, creating a supportive niche for tumor growth, invasion and metastasis [2].

Cancer-associated fibroblasts (CAFs): CAFs are a prominent stromal cell population within the TME that contribute to tumor progression through their ability to remodel the ECM, promote angiogenesis, and modulate immune responses. CAFs secrete growth factors, cytokines, and ECM-degrading enzymes that enhance tumor cell proliferation, invasion, and metastasis.

Immune cells: The immune microenvironment in breast cancer is characterized by a complex interplay between tumor-infiltrating lymphocytes (TILs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and regulatory T cells (Tregs). While TILs are associated with favorable prognosis and improved treatment response, other immune cell subsets, such as TAMs and Tregs, can promote tumor growth and immune evasion [3].

Angiogenic factors: Angiogenesis, the process of new blood vessel formation, plays a crucial role in tumor growth and metastasis by providing oxygen and nutrients to proliferating tumor cells. Angiogenic factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) promote angiogenesis in the TME and are attractive targets for anti-angiogenic therapies in breast cancer.

Targeting the tumor microenvironment: Several therapeutic strategies have been developed to target the TME and disrupt its tumor-promoting effects in breast cancer. These strategies encompass a range of approaches, including immunotherapy, angiogenesis inhibition, stromal targeting, and ECM modulation, each with its unique opportunities and challenges [4].

Immunotherapy: Immunotherapy has emerged as a promising treatment approach in breast cancer, harnessing the power of the immune system to recognize and eliminate tumor cells. Immune checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, have shown efficacy in subsets of breast cancer patients with immunogenic tumors or high TIL infiltration. However, response rates to immunotherapy remain modest in breast cancer compared to other malignancies, highlighting the need for biomarkers to identify patients most likely to benefit from these treatments [5].

Angiogenesis inhibition: Anti-angiogenic therapies targeting VEGF and other angiogenic factors have been extensively studied in breast cancer and have shown efficacy in combination with chemotherapy or targeted agents. However, resistance to anti-angiogenic therapies can develop over time, necessitating the development of alternative strategies to overcome resistance and improve treatment outcomes.

Stromal targeting: Targeting stromal components of the TME, such as CAFs and TAMs, represents an attractive therapeutic approach to disrupt tumor-stromal interactions and inhibit tumor growth. Preclinical studies have demonstrated the efficacy of CAF-targeted therapies, such as stromal depletion agents and CAF-specific inhibitors, in reducing tumor growth and metastasis in breast cancer models. However, translating these findings into clinical practice remains challenging due to the complexity of the TME and potential off-target effects on normal stromal cells [6].

ECM modulation: Alterations in the ECM composition and structure play a critical role in breast cancer progression and metastasis. Targeting ECM components, such as collagen and hyaluronic acid, with agents that disrupt ECM remodeling or promote ECM degradation has shown promise in preclinical models of breast cancer. However, clinical translation of ECM-targeted therapies faces hurdles related to drug delivery and specificity for tumor-associated ECM components.

Targeting the tumor microenvironment (TME) in breast cancer presents a promising avenue for improving treatment outcomes and patient survival. The TME comprises a complex network of stromal cells, immune cells, blood vessels, and extracellular matrix components that interact with tumor cells to regulate various aspects of cancer progression [7]. While significant progress has been made in understanding the role of the TME in breast cancer, several opportunities and challenges exist in harnessing this knowledge for therapeutic purposes.

Opportunities: Immunotherapy advancements: Immunotherapy has emerged as a groundbreaking treatment modality in breast cancer, capitalizing on the host immune system's ability to recognize and eliminate tumor cells. Targeting immune checkpoints, such as PD-1 and CTLA-4, has shown promise in subsets of breast cancer patients, particularly those with immunogenic tumors or high levels of tumor-infiltrating lymphocytes (TILs). Expanding our understanding of immune-tumor interactions within the TME offers opportunities for developing novel immunotherapeutic strategies and improving response rates in breast cancer patients.

Angiogenesis inhibition: Angiogenesis, the process of new blood vessel formation, is a hallmark of tumor progression and metastasis [8]. Targeting angiogenic factors, such as vascular endothelial growth factor (VEGF), has been a successful therapeutic strategy in breast cancer, leading to improved outcomes when combined with chemotherapy or targeted agents. Continued research into alternative anti-angiogenic approaches and overcoming resistance mechanisms holds promise for further enhancing the efficacy of anti-angiogenic therapies in breast cancer.

Stromal targeting: Cancer-associated fibroblasts (CAFs) and other stromal cell populations within the TME play a crucial role in promoting tumor growth and metastasis. Targeting these stromal components offers opportunities for disrupting tumor-stromal interactions and inhibiting tumor progression. Preclinical studies have shown promising results with CAF-targeted therapies, highlighting the potential for stromal targeting as a therapeutic strategy in breast cancer [9].

Challenges: TME heterogeneity: The TME in breast cancer is characterized by significant heterogeneity, both within individual tumors and between different patients. This heterogeneity poses challenges for developing effective TME-targeted therapies, as different tumor subtypes may exhibit distinct TME profiles and response patterns to treatment. Overcoming TME heterogeneity requires a deeper understanding of the molecular and cellular drivers of TME diversity and the development of personalized treatment approaches tailored to individual patient characteristics.

Treatment resistance: Adaptive changes in the TME can lead to treatment resistance, limiting the efficacy of TME-targeted therapies and contributing to disease progression. Resistance mechanisms may involve alterations in stromal cell signaling, immune evasion pathways, or angiogenic factor expression, among others. Overcoming treatment resistance requires the identification of biomarkers predictive of response and resistance to TME-targeted therapies, as well as the development of combination strategies that target multiple components of the TME simultaneously [10].

Off-target effects: TME-targeted therapies may inadvertently affect normal stromal cells and immune populations within the TME, leading to off-target effects and systemic toxicity. Achieving specificity for tumor-associated components of the TME while sparing normal tissues represents a significant challenge in the development of TME-targeted therapies. Strategies to minimize off-target effects include the use of targeted drug delivery systems, biomarker-guided treatment selection and combination therapies that enhance therapeutic efficacy while minimizing toxicity.

Targeting the TME in breast cancer presents both opportunities and challenges for improving treatment outcomes and patient survival. Advances in immunotherapy, angiogenesis inhibition and stromal targeting offer promising avenues for disrupting tumor-promoting interactions within the TME and enhancing treatment efficacy. However, overcoming TME heterogeneity, treatment resistance and off-target effects remains critical for realizing the full potential of TME-targeted therapies in breast cancer management. Continued research efforts and collaborative initiatives are needed to address these challenges and develop effective strategies for targeting the TME in breast cancer.

Discussion

Despite the promise of TME-targeted therapies in breast cancer treatment, several challenges must be addressed to maximize their clinical impact. TME heterogeneity, both within and between tumors, poses a significant obstacle to effective targeting of the TME, as different tumor subtypes may exhibit distinct TME profiles and response patterns to therapy. Additionally, treatment resistance, driven by adaptive changes in the TME, can limit the efficacy of TME-targeted therapies and lead to disease progression. Strategies to overcome these challenges include the development of combination therapies that target multiple components of the TME simultaneously and the identification of biomarkers predictive of treatment response and resistance.

Conclusion

In conclusion, targeting the TME represents a promising therapeutic strategy to improve outcomes in breast cancer patients. By disrupting the tumor-promoting effects of the TME and enhancing the efficacy of existing treatment modalities, TME-targeted therapies have the potential to transform breast cancer management and ultimately improve patient survival. However, addressing the challenges associated with TME-targeted therapies, such as TME heterogeneity and treatment resistance, will be critical for realizing the full clinical potential of these innovative approaches. Continued research efforts and collaborative initiatives are needed to advance our understanding of the TME and develop effective strategies for TME-targeted therapy in breast cancer.

References

1. Bluekens AMJ, Holland R, Karssemeijer N, Broeders MJM, den Heeten GJ, et al. (2012) Comparison of digital screening mammography and screen-film mammography in the early detection of clinically relevant cancers: A multicenter study. Radiology 265: 707-714.

Google Scholar, CrossRef

2. Ginsburg O, Yip CH, Brooks A, Cabanes A, Caleffi M, et al. (2020) Breast cancer early detection: A phased approach to implementation. Cancer 126: 2379

Google Scholar, CrossRef

3. Pashayan N, Antoniou AC, Ivanus U, Esserman LJ, Easton DF, et al. (2020) Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement. Nat Rev Clin Oncol 17: 716.

Google Scholar, CrossRef

4. La Vecchia C, Negri E, Carioli G (2022) Progress in cancer epidemiology: Avoided deaths in Europe over the last three decades. Eur J Cancer Prev 31: 388-392.

Google Scholar, CrossRef

5. Ouédraogo S, Dabakuyo TS, Gentil J, Poillot M.L, Dancourt V, et al. (2013) Attending breast cancer screening alone does not explain the detection of tumours at an early stage. Eur J Cancer Prev 22: 103-111.

Google Scholar, CrossRef

6. Trimboli RM, Giorgi Rossi P, Battisti NML, Cozzi A, Magni V, et al. (2020) Do we still need breast cancer screening in the era of targeted therapies and precision medicine? Insights Imaging 11:105.

Google Scholar, CrossRef

7. Park TS, Hwang ES (2016) Current trends in management of Ductal Carcinoma In Situ. Oncology 30: 823-831.

Google Scholar                

8. Neal CH, Joe AI, Patterson SK, Pujara AC, Helvie MA Digital (2021) mammography has persistently increased high-grade and overall DCIS detection without altering upgrade rate. AJR Am J Roentgenol 216: 912-918.

Google Scholar, CrossRef

9. Van Bockstal MR, Agahozo MC, Koppert LB, Deurzen CH (2020) A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. Int J Cancer 146: 1189-1197.

Google Scholar, CrossRef

10. Poiseuil M, Moutel G, Cosson M, Quertier MC, Duchange N (2023) Participation in breast cancer screening and its influence on other cancer screening invitations: Study in women aged 56 years old in four French departments. Eur J Cancer Prev.

Google Scholar, CrossRef